WASHINGTON and NESSA ZIONA, Israel, April 17, 2026 (GLOBE NEWSWIRE)-- Biolojic Design, a biotechnology company that uses AI to transform antibodies into multifunctional, programmable medicines, is ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
WASHINGTON and NESS ZIONA, Israel, March 25, 2026 (GLOBE NEWSWIRE)-- Biolojic Design, a biotechnology company that uses AI to transform antibodies into multifunctional, programmable medicines, today ...
Biolojic Design Ltd. has earned an additional milestone payment from its collaboration partner, Teva Pharmaceutical Industries Ltd., for TEV‘325 (TEV-56308, formerly BD-9), a multibody targeting IL-13 ...
- TEV ‘325, which targets IL-13 and TSLP, is being studied for the treatment of TH2-driven inflammatory diseases such as asthma and atopic dermatitis WASHINGTON and NESS ZIONA, Israel, March 25, 2026 ...
BD9 is a multibody that targets IL-13 and TSLP, and has potential to treat TH-2-driven inflammatory diseases BD9 designed using Biolojic’s Multibody Platform, which generates Antibodies capable of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results